Clinical

Dataset Information

0

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

ABSTRACT: This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.

DISEASE(S): Small Intestinal Cancer,Appendiceal Cancer,Colorectal Neoplasms,Intestinal Neoplasms,Appendiceal Neoplasms,Advanced Colorectal Cancer

PROVIDER: 2401233 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
| 2710011 | ecrin-mdr-crc
Clinical JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
| 2386408 | ecrin-mdr-crc
Clinical A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
| 2272421 | ecrin-mdr-crc
Genomics Shewanella bicestrii strain:JAB-1
| PRJNA393250 | ENA
Genomics Synechococcus sp. PEB' JAB'6FA
| PRJNA332360 | ENA
Genomics Synechococcus sp. PEB' JAB'6FD
| PRJNA332361 | ENA
Clinical A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
| 2275986 | ecrin-mdr-crc
Clinical A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
| 2278745 | ecrin-mdr-crc
Clinical First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
| 2309880 | ecrin-mdr-crc
Unknown The Research Progress of Direct KRAS G12C Mutation Inhibitors.
| S-EPMC8262225 | biostudies-literature